Physician profile
Steven Lobritto
NPI 1346229960
$88,347.59
in general payments reported to CMS, 2019-2025
9 companies · $29K in 2025
The $29K reported for 2025 was more than what 87% of Pediatric Transplant Hepatology providers received nationally (typical 2025 total: $425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,335 · 2022: $14K · 2023: $20K · 2024: $22K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $27K · Travel and Lodging: $8,838 · Food and Beverage: $3,747 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,140.50 |
| Consulting Fee | $26,705.00 |
| Travel and Lodging | $8,837.83 |
| Food and Beverage | $3,747.35 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $31,533.59 | 2023-2025 | Bylvay |
| Mirum Pharmaceuticals, INC. | $27,063.74 | 2022-2025 | Livmarli, Cholbam, Chenodal |
| Alexion Pharmaceuticals, INC. | $14,549.20 | 2022-2023 | |
| Albireo Pharma, INC. | $6,135.38 | 2023 | Bylvay |
| Gilead Sciences, INC. | $3,334.60 | 2019 | |
| Orphalan INC | $3,322.95 | 2023-2025 | Cuvrior |
| Mallinckrodt Hospital Products INC. | $2,388.00 | 2024 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $20.13 | 2023 | Gattex |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Lobritto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.